AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

ABIONYX Pharma Earnings Release 2019

Feb 4, 2020

1062_iss_2020-02-04_540d813e-3849-4b88-ae6e-e3cf5251515b.pdf

Earnings Release

Open in viewer

Opens in your device viewer

Press Release

Cash position and activity update for Q4 2019

Cash position of €8.3 million at 31 December 2019

Toulouse, FRANCE, Lakeland, UNITED-STATES, February 4, 2020, 8:30pm CET – ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, announces today that cash and cash equivalents totaled €8.3 million at December 31, 2019.

The activities of ABIONYX Pharma are focused on the discovery and development of innovative therapies to improve the lives of patients; the company did not generate any revenues during 2019, as expected.

As announced previously, possible collaborations with external partners are under consideration, and the company reasserts its commitment to communicating a new strategic development plan by the end of the first quarter of 2020.

About ABIONYX Pharma

ABIONYX Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients. The biotech assets inherited from CERENIS Therapeutics constitute a rich portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as a HDL targeted drug delivery platform in oncology, more specifically in immuno-oncology and chemotherapy.

Contacts :

NewCap Investor relations Louis-Victor Delouvrier [email protected] +33 (0)1 44 71 98 53